Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 210

1.

Allocating healthcare resources-seriously ill people should have priority.

Segall M.

BMJ. 2018 Apr 27;361:k1817. doi: 10.1136/bmj.k1817. No abstract available. Erratum in: BMJ. 2018 May 23;361:k2291.

PMID:
29703725
2.

WhichP450: a multi-class categorical model to predict the major metabolising CYP450 isoform for a compound.

Hunt PA, Segall MD, Tyzack JD.

J Comput Aided Mol Des. 2018 Apr;32(4):537-546. doi: 10.1007/s10822-018-0107-0. Epub 2018 Feb 20.

PMID:
29464466
3.

Brief Report: Relationship Between ADOS-2, Module 4 Calibrated Severity Scores (CSS) and Social and Non-Social Standardized Assessment Measures in Adult Males with Autism Spectrum Disorder (ASD).

Morrier MJ, Ousley OY, Caceres-Gamundi GA, Segall MJ, Cubells JF, Young LJ, Andari E.

J Autism Dev Disord. 2017 Dec;47(12):4018-4024. doi: 10.1007/s10803-017-3293-z.

PMID:
28875421
4.

A model-based assay design to reproduce in vivo patterns of acute drug-induced toxicity.

Kuepfer L, Clayton O, Thiel C, Cordes H, Nudischer R, Blank LM, Baier V, Heymans S, Caiment F, Roth A, Fluri DA, Kelm JM, Castell J, Selevsek N, Schlapbach R, Keun H, Hynes J, Sarkans U, Gmuender H, Herwig R, Niederer S, Schuchhardt J, Segall M, Kleinjans J.

Arch Toxicol. 2018 Jan;92(1):553-555. doi: 10.1007/s00204-017-2041-7. Epub 2017 Aug 29. No abstract available.

5.

Practical applications of matched series analysis: SAR transfer, binding mode suggestion and data point validation.

Hunt P, Segall M, O'Boyle N, Sayle R.

Future Med Chem. 2017 Jan;9(2):153-168. doi: 10.4155/fmc-2016-0203. Epub 2017 Jan 18.

PMID:
28097880
6.

Predicting Regioselectivity and Lability of Cytochrome P450 Metabolism Using Quantum Mechanical Simulations.

Tyzack JD, Hunt PA, Segall MD.

J Chem Inf Model. 2016 Nov 28;56(11):2180-2193. Epub 2016 Oct 26.

PMID:
27753488
7.

Does aquatic foraging impact head shape evolution in snakes?

Segall M, Cornette R, Fabre AC, Godoy-Diana R, Herrel A.

Proc Biol Sci. 2016 Aug 31;283(1837). pii: 20161645. doi: 10.1098/rspb.2016.1645.

8.

Avoiding Missed Opportunities by Analyzing the Sensitivity of Our Decisions.

Segall MD, Yusof I, Champness EJ.

J Med Chem. 2016 May 12;59(9):4267-77. doi: 10.1021/acs.jmedchem.5b01921. Epub 2016 Mar 18.

PMID:
26901568
9.

High-contrast filtering by multipass diffraction between paired volume Bragg gratings.

Ott D, SeGall M, Divliansky I, Venus G, Glebov L.

Appl Opt. 2015 Nov 1;54(31):9065-70. doi: 10.1364/AO.54.009065.

PMID:
26560557
10.

Evaluation of an Anal Insert Device for the Conservative Management of Fecal Incontinence.

Lukacz ES, Segall MM, Wexner SD.

Dis Colon Rectum. 2015 Sep;58(9):892-8. doi: 10.1097/DCR.0000000000000427.

PMID:
26252852
11.

The challenges of making decisions using uncertain data.

Segall MD, Champness EJ.

J Comput Aided Mol Des. 2015 Sep;29(9):809-16. doi: 10.1007/s10822-015-9855-2. Epub 2015 Jul 1.

PMID:
26126976
12.

Breaking free from chemical spreadsheets.

Segall M, Champness E, Leeding C, Chisholm J, Hunt P, Elliott A, Garcia-Martinez H, Foster N, Dowling S.

Drug Discov Today. 2015 Sep;20(9):1093-103. doi: 10.1016/j.drudis.2015.03.008. Epub 2015 Jun 4. Review.

PMID:
26050579
13.

Advances in multiparameter optimization methods for de novo drug design.

Segall M.

Expert Opin Drug Discov. 2014 Jul;9(7):803-17. doi: 10.1517/17460441.2014.913565. Epub 2014 May 3. Review.

PMID:
24793080
14.

Stabilization system for holographic recording of volume Bragg gratings using a corner cube retroreflector.

Ott DB, Divliansky IB, Segall MA, Glebov LB.

Appl Opt. 2014 Feb 20;53(6):1039-46. doi: 10.1364/AO.53.001039.

PMID:
24663299
15.

Alternative variables in drug discovery: promises and challenges.

Abad-Zapatero C, Champness EJ, Segall MD.

Future Med Chem. 2014 Apr;6(5):577-93. doi: 10.4155/fmc.14.16.

PMID:
24649959
16.

Addressing toxicity risk when designing and selecting compounds in early drug discovery.

Segall MD, Barber C.

Drug Discov Today. 2014 May;19(5):688-93. doi: 10.1016/j.drudis.2014.01.006. Epub 2014 Jan 19. Review.

PMID:
24451294
17.

Finding the rules for successful drug optimisation.

Yusof I, Shah F, Hashimoto T, Segall MD, Greene N.

Drug Discov Today. 2014 May;19(5):680-7. doi: 10.1016/j.drudis.2014.01.005. Epub 2014 Jan 19. Review.

PMID:
24451293
18.

Effect of aberrations in a holographic system on reflecting volume Bragg gratings.

SeGall M, Ott D, Divliansky I, Glebov LB.

Appl Opt. 2013 Nov 10;52(32):7826-31. doi: 10.1364/AO.52.007826.

PMID:
24216744
19.

Impact of temperature on performance in two species of South African dwarf chameleon, Bradypodion pumilum and B. occidentale.

Segall M, Tolley KA, Vanhooydonck B, Measey GJ, Herrel A.

J Exp Biol. 2013 Oct 15;216(Pt 20):3828-36. doi: 10.1242/jeb.092353. Epub 2013 Jul 18.

20.

Considering the impact drug-like properties have on the chance of success.

Yusof I, Segall MD.

Drug Discov Today. 2013 Jul;18(13-14):659-66. doi: 10.1016/j.drudis.2013.02.008. Epub 2013 Feb 28. Review.

PMID:
23458995
21.

Quality of life impact in women with accidental bowel leakage.

Brown HW, Wexner SD, Segall MM, Brezoczky KL, Lukacz ES.

Int J Clin Pract. 2012 Nov;66(11):1109-16. doi: 10.1111/ijcp.12017.

PMID:
23067035
22.

Accidental bowel leakage in the mature women's health study: prevalence and predictors.

Brown HW, Wexner SD, Segall MM, Brezoczky KL, Lukacz ES.

Int J Clin Pract. 2012 Nov;66(11):1101-8. doi: 10.1111/ijcp.12018.

PMID:
23067034
23.

Binary volume phase masks in photo-thermo-refractive glass.

SeGall M, Rotar V, Lumeau J, Mokhov S, Zeldovich B, Glebov LB.

Opt Lett. 2012 Apr 1;37(7):1190-2. doi: 10.1364/OL.37.001190.

PMID:
22466191
24.
25.

Can we really do computer-aided drug design?

Segall M.

J Comput Aided Mol Des. 2012 Jan;26(1):121-4. doi: 10.1007/s10822-011-9512-3. Epub 2011 Dec 11.

PMID:
22160553
26.

Applying medicinal chemistry transformations and multiparameter optimization to guide the search for high-quality leads and candidates.

Segall M, Champness E, Leeding C, Lilien R, Mettu R, Stevens B.

J Chem Inf Model. 2011 Nov 28;51(11):2967-76. doi: 10.1021/ci2003208. Epub 2011 Oct 18.

PMID:
21981548
27.

The risks of subconscious biases in drug-discovery decision making.

Segall M, Chadwick A.

Future Med Chem. 2011 May;3(7):771-4. doi: 10.4155/fmc.11.33. No abstract available.

28.

Guiding effective decisions: an interview with Matthew Segall, CEO of Optibrium. Interview by Wendy A. Warr.

Segall M.

J Comput Aided Mol Des. 2011 Feb;25(2):103-6. doi: 10.1007/s10822-011-9411-7. Epub 2011 Jan 12. No abstract available.

PMID:
21225445
29.

Making priors a priority.

Segall M, Chadwick A.

J Comput Aided Mol Des. 2010 Dec;24(12):957-60. doi: 10.1007/s10822-010-9388-7. Epub 2010 Oct 16.

PMID:
20953670
30.

Overcoming psychological barriers to good discovery decisions.

Chadwick AT, Segall MD.

Drug Discov Today. 2010 Jul;15(13-14):561-9. doi: 10.1016/j.drudis.2010.05.007. Epub 2010 May 27. Review.

PMID:
20553956
31.

Gaussian processes for classification: QSAR modeling of ADMET and target activity.

Obrezanova O, Segall MD.

J Chem Inf Model. 2010 Jun 28;50(6):1053-61. doi: 10.1021/ci900406x.

PMID:
20433177
32.

Time averaging of NMR chemical shifts in the MLF peptide in the solid state.

De Gortari I, Portella G, Salvatella X, Bajaj VS, van der Wel PC, Yates JR, Segall MD, Pickard CJ, Payne MC, Vendruscolo M.

J Am Chem Soc. 2010 May 5;132(17):5993-6000. doi: 10.1021/ja9062629.

PMID:
20387894
33.

Beyond profiling: using ADMET models to guide decisions.

Segall M, Champness E, Obrezanova O, Leeding C.

Chem Biodivers. 2009 Nov;6(11):2144-51. doi: 10.1002/cbdv.200900148.

PMID:
19937845
34.

Automatic QSAR modeling of ADME properties: blood-brain barrier penetration and aqueous solubility.

Obrezanova O, Gola JM, Champness EJ, Segall MD.

J Comput Aided Mol Des. 2008 Jun-Jul;22(6-7):431-40. doi: 10.1007/s10822-008-9193-8. Epub 2008 Feb 14.

PMID:
18273554
35.

Evidence-based assessment of cognitive functioning in pediatric psychology.

Campbell JM, Brown RT, Cavanagh SE, Vess SF, Segall MJ.

J Pediatr Psychol. 2008 Oct;33(9):999-1014; discussion 1015-20. doi: 10.1093/jpepsy/jsm138. Epub 2008 Jan 13. Review.

36.

Theoretical investigations of oxygen-17 NMR chemical shifts to discriminate among helical forms.

De Gortari I, Galván M, Ireta J, Segall M, Pickard CJ, Payne M.

J Phys Chem A. 2007 Dec 20;111(50):13099-105. Epub 2007 Nov 17.

PMID:
18020316
37.

Rural health care in Vietnam and China: conflict between market reforms and social need.

Huong DB, Phuong NK, Bales S, Jiaying C, Lucas H, Segall M.

Int J Health Serv. 2007;37(3):555-72.

PMID:
17844934
38.

Gaussian processes: a method for automatic QSAR modeling of ADME properties.

Obrezanova O, Csanyi G, Gola JM, Segall MD.

J Chem Inf Model. 2007 Sep-Oct;47(5):1847-57. Epub 2007 Jun 28.

PMID:
17602549
39.

Effect of Asp69 and Arg310 on the pK of His68, a key catalytic residue of adenylosuccinate lyase.

Sivendran S, Segall ML, Rancy PC, Colman RF.

Protein Sci. 2007 Aug;16(8):1700-7. Epub 2007 Jun 28.

40.

Substrate and product complexes of Escherichia coli adenylosuccinate lyase provide new insights into the enzymatic mechanism.

Tsai M, Koo J, Yip P, Colman RF, Segall ML, Howell PL.

J Mol Biol. 2007 Jul 13;370(3):541-54. Epub 2007 May 4.

41.
42.

Focus on success: using a probabilistic approach to achieve an optimal balance of compound properties in drug discovery.

Segall MD, Beresford AP, Gola JM, Hawksley D, Tarbit MH.

Expert Opin Drug Metab Toxicol. 2006 Apr;2(2):325-37. Review.

PMID:
16866617
43.
44.

In silico prediction of ADME properties: are we making progress?

Beresford AP, Segall M, Tarbit MH.

Curr Opin Drug Discov Devel. 2004 Jan;7(1):36-42. Review.

PMID:
14982146
45.

District health systems in a neoliberal world: a review of five key policy areas.

Segall M.

Int J Health Plann Manage. 2003 Oct-Dec;18 Suppl 1:S5-26. Review.

PMID:
14661938
46.

Graft-vs-host disease after solid organ transplant.

Gulbahce HE, Brown CA, Wick M, Segall M, Jessurun J.

Am J Clin Pathol. 2003 Apr;119(4):568-73.

PMID:
12710129
47.

Positive remote crossmatch: impact on short-term and long-term outcome in cadaver renal transplantation.

Noreen HJ, McKinley DM, Gillingham KJ, Matas AJ, Segall M.

Transplantation. 2003 Feb 27;75(4):501-5.

PMID:
12605118
48.

Smart high-throughput screening.

Segall M.

Drug Discov Today. 2003 Feb 15;8(4):160-1. No abstract available.

PMID:
12581709
49.

HLA alloimmunization in patients requiring ventricular assist device support.

McKenna DH Jr, Eastlund T, Segall M, Noreen HJ, Park S.

J Heart Lung Transplant. 2002 Nov;21(11):1218-24.

PMID:
12431496
50.

Influence of apoE domain structure and polymorphism on the kinetics of phospholipid vesicle solubilization.

Segall ML, Dhanasekaran P, Baldwin F, Anantharamaiah GM, Weisgraber KH, Phillips MC, Lund-Katz S.

J Lipid Res. 2002 Oct;43(10):1688-700.

Supplemental Content

Loading ...
Support Center